Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 9
Encontrada(s) 1 página(s)

IRTA Pubpro. Open Digital Archive
Publication Artículo científico (JournalArticle)

Describing variability in pig genes involved in coronavirus infections for a One Health perspective in conservation of animal genetic resources

  • Bovo, Samuele
  • Schiavo, Giuseppina
  • Ribani, Anisa
  • Utzeri, Valerio J.
  • Taurisano, Valeria
  • Ballan, Mohamad
  • Muñoz, Maria
  • Alves, Estefania
  • Araujo, Jose P.
  • Bozzi, Riccardo
  • Charneca, Rui
  • Di Palma, Federica
  • Djurkin Kušec, Ivona
  • Etherington, Graham
  • Fernandez, Ana I.
  • García, Fabián
  • García-Casco, Juan
  • Karolyi, Danijel
  • Gallo, Maurizio
  • Martins, José Manuel
  • Mercat, Marie-José
  • Núñez, Yolanda
  • Quintanilla, Raquel
  • Radović, Čedomir
  • Razmaite, Violeta
  • Riquet, Juliette
  • Savić, Radomir
  • Škrlep, Martin
  • Usai, Graziano
  • Zimmer, Christoph
  • Ovilo, Cristina
  • Fontanesi, Luca
Coronaviruses silently circulate in human and animal populations, causing mild to severe diseases. Therefore, livestock are important components of a “One Health” perspective aimed to control these viral infections. However, at present there is no example that considers pig genetic resources in this context. In this study, we investigated the variability of four genes (ACE2, ANPEP and DPP4 encoding for host receptors of the viral spike proteins and TMPRSS2 encoding for a host proteinase) in 23 European (19 autochthonous and three commercial breeds and one wild boar population) and two Asian Sus scrofa populations. A total of 2229 variants were identified in the four candidate genes: 26% of them were not previously described; 29 variants affected the protein sequence and might potentially interact with the infection mechanisms. The results coming from this work are a first step towards a “One Health” perspective that should consider conservation programs of pig genetic resources with twofold objectives: (i) genetic resources could be reservoirs of host gene variability useful to design selection programs to increase resistance to coronaviruses; (ii) the described variability in genes involved in coronavirus infections across many different pig populations might be part of a risk assessment including pig genetic resources., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de la UB
Publication Artículo científico (JournalArticle)

Unveiling the Effect of Low pH on the SARS-CoV-2 Main Protease by Molecular Dynamics Simulations

  • Barazorda-Ccahuana, Haruna L.
  • Nedyalkova, Miroslava
  • Mas i Pujadas, Francesc
  • Madurga Díez, Sergio
(1) Background: Main Protease (Mpro) is an attractive therapeutic target that acts in the replication and transcription of the SARS-CoV-2 coronavirus. Mpro is rich in residues exposed to protonation/deprotonation changes which could affect its enzymatic function. This work aimed to explore the effect of the protonation/deprotonation states of Mpro at different pHs using computa- tional techniques. (2) Methods: The different distribution charges were obtained in all the evaluated pHs by the Semi-Grand Canonical Monte Carlo (SGCMC) method. A set of Molecular Dynamics (MD) simulations was performed to consider the different protonation/deprotonation during 250 ns, verifying the structural stability of Mpro at different pHs. (3) Results: The present findings demon- strate that active site residues and residues that allow Mpro dimerisation was not affected by pH changes. However, Mpro substrate-binding residues were altered at low pHs, allowing the increased pocket volume. Additionally, the results of the solvent distribution around Sγ, Hγ, Nδ1 and Hδ1 atoms of the catalytic residues Cys145 and His41 showed a low and high-water affinity at acidic pH, respectively. It which could be crucial in the catalytic mechanism of SARS-CoV-2 Mpro at low pHs. Moreover, we analysed the docking interactions of PF-00835231 from Pfizer in the preclinical phase, which shows excellent affinity with the Mpro at different pHs. (4) Conclusion: Overall, these findings indicate that SARS-CoV-2 Mpro is highly stable at acidic pH conditions, and this inhibitor could have a desirable function at this condition.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Unveiling the Effect of Low pH on the SARS-CoV-2 Main Protease by Molecular Dynamics Simulations

  • Barazorda-Ccahuana, Haruna L.
  • Nedyalkova, Miroslava
  • Mas i Pujadas, Francesc
  • Madurga Díez, Sergio
(1) Background: Main Protease (Mpro) is an attractive therapeutic target that acts in the replication and transcription of the SARS-CoV-2 coronavirus. Mpro is rich in residues exposed to protonation/deprotonation changes which could affect its enzymatic function. This work aimed to explore the effect of the protonation/deprotonation states of Mpro at different pHs using computa- tional techniques. (2) Methods: The different distribution charges were obtained in all the evaluated pHs by the Semi-Grand Canonical Monte Carlo (SGCMC) method. A set of Molecular Dynamics (MD) simulations was performed to consider the different protonation/deprotonation during 250 ns, verifying the structural stability of Mpro at different pHs. (3) Results: The present findings demon- strate that active site residues and residues that allow Mpro dimerisation was not affected by pH changes. However, Mpro substrate-binding residues were altered at low pHs, allowing the increased pocket volume. Additionally, the results of the solvent distribution around Sγ, Hγ, Nδ1 and Hδ1 atoms of the catalytic residues Cys145 and His41 showed a low and high-water affinity at acidic pH, respectively. It which could be crucial in the catalytic mechanism of SARS-CoV-2 Mpro at low pHs. Moreover, we analysed the docking interactions of PF-00835231 from Pfizer in the preclinical phase, which shows excellent affinity with the Mpro at different pHs. (4) Conclusion: Overall, these findings indicate that SARS-CoV-2 Mpro is highly stable at acidic pH conditions, and this inhibitor could have a desirable function at this condition.
Recercat. Dipósit de la Recerca de Catalunya
Publication Artículo científico (JournalArticle)

Describing variability in pig genes involved in coronavirus infections for a One Health perspective in conservation of animal genetic resources

  • Bovo, Samuele
  • Schiavo, Giuseppina
  • Ribani, Anisa
  • Utzeri, Valerio J.
  • Taurisano, Valeria
  • Ballan, Mohamad
  • Muñoz, Maria
  • Alves, Estefania
  • Araujo, Jose P.
  • Bozzi, Riccardo
  • Charneca, Rui
  • Di Palma, Federica
  • Djurkin Kušec, Ivona
  • Etherington, Graham
  • Fernandez, Ana I.
  • García, Fabián
  • García-Casco, Juan
  • Karolyi, Danijel
  • Gallo, Maurizio
  • Martins, José Manuel
  • Mercat, Marie-José
  • Núñez, Yolanda
  • Quintanilla, Raquel
  • Radović, Čedomir
  • Razmaite, Violeta
  • Riquet, Juliette
  • Savić, Radomir
  • Škrlep, Martin
  • Usai, Graziano
  • Zimmer, Christoph
  • Ovilo, Cristina
  • Fontanesi, Luca
Coronaviruses silently circulate in human and animal populations, causing mild to severe diseases. Therefore, livestock are important components of a “One Health” perspective aimed to control these viral infections. However, at present there is no example that considers pig genetic resources in this context. In this study, we investigated the variability of four genes (ACE2, ANPEP and DPP4 encoding for host receptors of the viral spike proteins and TMPRSS2 encoding for a host proteinase) in 23 European (19 autochthonous and three commercial breeds and one wild boar population) and two Asian Sus scrofa populations. A total of 2229 variants were identified in the four candidate genes: 26% of them were not previously described; 29 variants affected the protein sequence and might potentially interact with the infection mechanisms. The results coming from this work are a first step towards a “One Health” perspective that should consider conservation programs of pig genetic resources with twofold objectives: (i) genetic resources could be reservoirs of host gene variability useful to design selection programs to increase resistance to coronaviruses; (ii) the described variability in genes involved in coronavirus infections across many different pig populations might be part of a risk assessment including pig genetic resources., info:eu-repo/semantics/publishedVersion
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The impact of frailty on survival in elderly intensive care patients with COVID-19, the COVIP study

  • Jung, Christian|||0000-0001-8325-250X
  • Flaatten, Hans|||0000-0001-9186-3482
  • Fjølner, Jesper|||0000-0003-3371-0503
  • Bruno, Raphael Romano|||0000-0003-3776-3530
  • Wernly, Bernhard|||0000-0003-4024-0220
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Bollen Pinto, Bernardo|||0000-0002-1281-543X
  • Schefold, Joerg C.|||0000-0001-9162-5724
  • Wolff, Georg|||0000-0002-1734-6177
  • Kelm, Malte|||0000-0003-0060-1052
  • Beil, Michael|||0000-0002-7233-6254
  • Sviri, Sigal|||0000-0002-9213-0245
  • van Heerden, Peter Vernon
  • Szczeklik, Wojciech|||0000-0002-1349-1123
  • Czuczwar, Miroslaw|||0000-0002-9025-6717
  • Elhadi, Muhammed|||0000-0001-6406-4212
  • Joannidis, Michael
  • Oeyen, Sandra|||0000-0001-6880-7167
  • Zafeiridis, Tilemachos|||0000-0001-5020-312X
  • Marsh, Brian|||0000-0002-6711-6628
  • Andersen, Finn H.|||0000-0003-3775-7325
  • Moreno, Rui|||0000-0002-9795-8316
  • Cecconi, Maurizio|||0000-0002-4376-6538
  • Leaver, Susannah|||0000-0003-0647-1471
  • Boumendil, Ariane
  • De Lange, Dylan W.|||0000-0002-0191-7270
  • Guidet, Bertrand|||0000-0002-7643-6770
The COVID-19 pandemic has led highly developed healthcare systems to the brink of collapse due to the large numbers of patients being admitted into hospitals. One of the potential prognostic indicators in patients with COVID-19 is frailty. The degree of frailty could be used to assist both the triage into intensive care, and decisions regarding treatment limitations. Our study sought to determine the interaction of frailty and age in elderly COVID-19 ICU patients. A prospective multicentre study of COVID-19 patients ≥ 70 years admitted to intensive care in 138 ICUs from 28 countries was conducted. The primary endpoint was 30-day mortality. Frailty was assessed using the clinical frailty scale. Additionally, comorbidities, management strategies and treatment limitations were recorded. The study included 1346 patients (28% female) with a median age of 75 years (IQR 72-78, range 70-96), 16.3% were older than 80 years, and 21% of the patients were frail. The overall survival at 30 days was 59% (95% CI 56-62), with 66% (63-69) in fit, 53% (47-61) in vulnerable and 41% (35-47) in frail patients (p < 0.001). In frail patients, there was no difference in 30-day survival between different age categories. Frailty was linked to an increased use of treatment limitations and less use of mechanical ventilation. In a model controlling for age, disease severity, sex, treatment limitations and comorbidities, frailty was independently associated with lower survival. Frailty provides relevant prognostic information in elderly COVID-19 patients in addition to age and comorbidities. Trial registration Clinicaltrials.gov: , registered 19 March 2020. The online version contains supplementary material available at 10.1186/s13054-021-03551-3.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Disease-Course Adapting Machine Learning Prognostication Models in Elderly Patients Critically Ill With COVID-19, Multicenter Cohort Study With External Validation

  • Jung, Christian|||0000-0001-8325-250X
  • Mamandipoor, Behrooz|||0000-0001-9441-3815
  • Fjølner, Jesper|||0000-0003-3371-0503
  • Bruno, Raphael Romano|||0000-0003-3776-3530
  • Wernly, Bernhard|||0000-0003-4024-0220
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Bollen Pinto, Bernardo|||0000-0002-1281-543X
  • Schefold, Joerg C.|||0000-0001-9162-5724
  • Wolff, Georg|||0000-0002-1734-6177
  • Kelm, Malte|||0000-0003-0060-1052
  • Beil, Michael|||0000-0002-7233-6254
  • Sviri, Sigal|||0000-0002-9213-0245
  • van Heerden, Peter V.|||0000-0003-0621-0626
  • Szczeklik, Wojciech|||0000-0002-1349-1123
  • Czuczwar, Miroslaw|||0000-0002-9025-6717
  • Elhadi, Muhammed|||0000-0001-6406-4212
  • Joannidis, Michael
  • Oeyen, Sandra|||0000-0001-6880-7167
  • Zafeiridis, Tilemachos|||0000-0001-5020-312X
  • Marsh, Brian|||0000-0002-6711-6628
  • Andersen, Finn H.|||0000-0003-3775-7325
  • Moreno, Rui|||0000-0002-9795-8316
  • Cecconi, Maurizio|||0000-0002-4376-6538
  • Leaver, Susannah|||0000-0003-0647-1471
  • De Lange, Dylan W.|||0000-0002-0191-7270
  • Guidet, Bertrand|||0000-0002-7643-6770
  • Flaatten, Hans|||0000-0001-9186-3482
  • Osmani, Venet|||0000-0001-7306-2972
The COVID-19 pandemic caused by SARS-CoV-2 is challenging health care systems globally. The disease disproportionately affects the elderly population, both in terms of disease severity and mortality risk. The aim of this study was to evaluate machine learning-based prognostication models for critically ill elderly COVID-19 patients, which dynamically incorporated multifaceted clinical information on evolution of the disease. This multicenter cohort study (COVIP study) obtained patient data from 151 intensive care units (ICUs) from 26 countries. Different models based on the Sequential Organ Failure Assessment (SOFA) score, logistic regression (LR), random forest (RF), and extreme gradient boosting (XGB) were derived as baseline models that included admission variables only. We subsequently included clinical events and time-to-event as additional variables to derive the final models using the same algorithms and compared their performance with that of the baseline group. Furthermore, we derived baseline and final models on a European patient cohort, which were externally validated on a non-European cohort that included Asian, African, and US patients. In total, 1432 elderly (≥70 years old) COVID-19-positive patients admitted to an ICU were included for analysis. Of these, 809 (56.49%) patients survived up to 30 days after admission. The average length of stay was 21.6 (SD 18.2) days. Final models that incorporated clinical events and time-to-event information provided superior performance (area under the receiver operating characteristic curve of 0.81; 95% CI 0.804-0.811), with respect to both the baseline models that used admission variables only and conventional ICU prediction models (SOFA score, P <.001). The average precision increased from 0.65 (95% CI 0.650-0.655) to 0.77 (95% CI 0.759-0.770). Integrating important clinical events and time-to-event information led to a superior accuracy of 30-day mortality prediction compared with models based on the admission information and conventional ICU prediction models. This study shows that machine-learning models provide additional information and may support complex decision-making in critically ill elderly COVID-19 patients. ClinicalTrials.gov NCT04321265; https://clinicaltrials.gov/ct2/show/NCT04321265.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

COVID-19 machine learning model predicts outcomes in older patients from various European countries, between pandemic waves, and in a cohort of Asian, African, and American patients

  • Mamandipoor, Behrooz|||0000-0001-9441-3815
  • Bruno, Raphael Romano|||0000-0003-3776-3530
  • Wernly, Bernhard|||0000-0003-4024-0220
  • Wolff, Georg|||0000-0002-1734-6177
  • Fjølner, Jesper|||0000-0003-3371-0503
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Pinto, Bernardo Bollen
  • Schefold, Joerg C.|||0000-0001-9162-5724
  • Kelm, Malte|||0000-0003-0060-1052
  • Beil, Michael|||0000-0002-7233-6254
  • Sigal, Sviri
  • Leaver, Susannah|||0000-0003-0647-1471
  • De Lange, Dylan W.|||0000-0002-0191-7270
  • Guidet, Bertrand|||0000-0002-7643-6770
  • Flaatten, Hans|||0000-0001-9186-3482
  • Szczeklik, Wojciech|||0000-0002-1349-1123
  • Jung, Christian|||0000-0001-8325-250X
  • Osmani, Venet|||0000-0001-7306-2972
COVID-19 remains a complex disease in terms of its trajectory and the diversity of outcomes rendering disease management and clinical resource allocation challenging. Varying symptomatology in older patients as well as limitation of clinical scoring systems have created the need for more objective and consistent methods to aid clinical decision making. In this regard, machine learning methods have been shown to enhance prognostication, while improving consistency. However, current machine learning approaches have been limited by lack of generalisation to diverse patient populations, between patients admitted at different waves and small sample sizes. We sought to investigate whether machine learning models, derived on routinely collected clinical data, can generalise well i) between European countries, ii) between European patients admitted at different COVID-19 waves, and iii) between geographically diverse patients, namely whether a model derived on the European patient cohort can be used to predict outcomes of patients admitted to Asian, African and American ICUs. We compare Logistic Regression, Feed Forward Neural Network and XGBoost algorithms to analyse data from 3,933 older patients with a confirmed COVID-19 diagnosis in predicting three outcomes, namely: ICU mortality, 30-day mortality and patients at low risk of deterioration. The patients were admitted to ICUs located in 37 countries, between January 11, 2020, and April 27, 2021. The XGBoost model derived on the European cohort and externally validated in cohorts of Asian, African, and American patients, achieved AUC of 0.89 (95% CI 0.89-0.89) in predicting ICU mortality, AUC of 0.86 (95% CI 0.86-0.86) for 30-day mortality prediction and AUC of 0.86 (95% CI 0.86-0.86) in predicting low-risk patients. Similar AUC performance was achieved also when predicting outcomes between European countries and between pandemic waves, while the models showed high calibration quality. Furthermore, saliency analysis showed that FiO2 values of up to 40% do not appear to increase the predicted risk of ICU and 30-day mortality, while PaO2 values of 75 mmHg or lower are associated with a sharp increase in the predicted risk of ICU and 30-day mortality. Lastly, increase in SOFA scores also increase the predicted risk, but only up to a value of 8. Beyond these scores the predicted risk remains consistently high. The models captured both the dynamic course of the disease as well as similarities and differences between the diverse patient cohorts, enabling prediction of disease severity, identification of low-risk patients and potentially supporting effective planning of essential clinical resources. COVID-19 remains a complex disease, making it challenging to estimate the risk of deterioration of critically ill patients and consequently allocation of clinical resources, such as ventilators. As a result, there is a need to support clinical decision making through objective methods and address some of the limitations of the current clinical scoring systems. In response, we developed machine learning models using routine clinical data of patients from 37 countries worldwide, including 18 European countries. We find that: i) machine learning models can predict outcomes in patients from diverse European countries, that is which patients have a low risk of deterioration and which may require increased care such that resources are allocated efficiently; ii) routine clinical data from European patients can be used to predict outcomes in non-European patients, namely those admitted in Asian, African, and American intensive care units, without significantly affecting the performance, and iii) routine clinical data collected during the first COVID-19 pandemic wave, can be used to predict the risk of deterioration of patients admitted during subsequent waves. Our study is the first step towards improving standardisation and equity of critical care across healthcare institutions and further afield across diverse countries and territories.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Association of chronic heart failure with mortality in old intensive care patients suffering from Covid-19

  • Bruno, Raphael Romano|||0000-0003-3776-3530
  • Wernly, Bernhard|||0000-0003-4024-0220
  • Wolff, Georg|||0000-0002-1734-6177
  • Fjølner, Jesper|||0000-0003-3371-0503
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Bollen Pinto, Bernardo|||0000-0002-1281-543X
  • Schefold, Joerg C.|||0000-0001-9162-5724
  • Kindgen-Milles, Detlef
  • Baldia, Philipp Heinrich
  • Kelm, Malte|||0000-0003-0060-1052
  • Beil, Michael|||0000-0002-7233-6254
  • Sviri, Sigal|||0000-0002-9213-0245
  • van Heerden, Peter Vernon
  • Szczeklik, Wojciech|||0000-0002-1349-1123
  • Topeli, Arzu
  • Elhadi, Muhammed|||0000-0001-6406-4212
  • Joannidis, Michael
  • Oeyen, Sandra|||0000-0001-6880-7167
  • Kondili, Eumorfia
  • Marsh, Brian|||0000-0002-6711-6628
  • Andersen, Finn H.|||0000-0003-3775-7325
  • Moreno, Rui|||0000-0002-9795-8316
  • Leaver, Susannah|||0000-0003-0647-1471
  • Boumendil, Ariane
  • De Lange, Dylan W.|||0000-0002-0191-7270
  • Guidet, Bertrand|||0000-0002-7643-6770
  • Flaatten, Hans|||0000-0001-9186-3482
  • Jung, Christian|||0000-0001-8325-250X
Chronic heart failure (CHF) is a major risk factor for mortality in coronavirus disease 2019 (COVID-19). This prospective international multicentre study investigates the role of pre-existing CHF on clinical outcomes of critically ill old (≥70 years) intensive care patients with COVID-19. Patients with pre-existing CHF were subclassified as having ischaemic or non-ischaemic cardiac disease; patients with a documented ejection fraction (EF) were subclassified according to heart failure EF: reduced (HFrEF, n = 132), mild (HFmrEF, n = 91), or preserved (HFpEF, n = 103). Associations of heart failure characteristics with the 30 day mortality were analysed in univariate and multivariate logistic regression analyses. Pre-existing CHF was reported in 566 of 3917 patients (14%). Patients with CHF were older, frailer, and had significantly higher SOFA scores on admission. CHF patients showed significantly higher crude 30 day mortality [60% vs. 48%, P < 0.001; odds ratio 1.87, 95% confidence interval (CI) 1.5-2.3] and 3 month mortality (69% vs. 56%, P < 0.001). After multivariate adjustment for confounders (SOFA, age, sex, and frailty), no independent association of CHF with mortality remained [adjusted odds ratio (aOR) 1.2, 95% CI 0.5-1.5; P = 0.137]. More patients suffered from pre-existing ischaemic than from non-ischaemic disease [233 vs. 328 patients (n = 5 unknown aetiology)]. There were no differences in baseline characteristics between ischaemic and non-ischaemic disease or between HFrEF, HFmrEF, and HFpEF. Crude 30 day mortality was significantly higher in HFrEF compared with HFpEF (64% vs. 48%, P = 0.042). EF as a continuous variable was not independently associated with 30 day mortality (aOR 0.98, 95% CI 0.9-1.0; P = 0.128). In critically ill older COVID-19 patients, pre-existing CHF was not independently associated with 30 day mortality. Trial registration number: NCT04321265.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Lactate is associated with mortality in very old intensive care patients suffering from COVID-19, results from an international observational study of 2860 patients

  • Bruno, Raphael Romano|||0000-0003-3776-3530
  • Wernly, Bernhard|||0000-0003-4024-0220
  • Flaatten, Hans|||0000-0001-9186-3482
  • Fjølner, Jesper|||0000-0003-3371-0503
  • Artigas Raventós, Antoni|||0000-0002-8029-1017
  • Bollen Pinto, Bernardo|||0000-0002-1281-543X
  • Schefold, Joerg C.|||0000-0001-9162-5724
  • Binnebössel, Stephan
  • Baldia, Philipp Heinrich
  • Kelm, Malte|||0000-0003-0060-1052
  • Beil, Michael|||0000-0002-7233-6254
  • Sigal, Sivri
  • van Heerden, Peter Vernon
  • Szczeklik, Wojciech|||0000-0002-1349-1123
  • Elhadi, Muhammed|||0000-0001-6406-4212
  • Joannidis, Michael
  • Oeyen, Sandra|||0000-0001-6880-7167
  • Zafeiridis, Tilemachos|||0000-0001-5020-312X
  • Wollborn, Jakob
  • Arche Banzo, Maria José
  • Fuest, Kristina
  • Marsh, Brian|||0000-0002-6711-6628
  • Andersen, Finn H.|||0000-0003-3775-7325
  • Moreno, Rui|||0000-0002-9795-8316
  • Leaver, Susannah|||0000-0003-0647-1471
  • Boumendil, Ariane
  • De Lange, Dylan W.|||0000-0002-0191-7270
  • Guidet, Bertrand|||0000-0002-7643-6770
  • Jung, Christian|||0000-0001-8325-250X
Lactate is an established prognosticator in critical care. However, there still is insufficient evidence about its role in predicting outcome in COVID-19. This is of particular concern in older patients who have been mostly affected during the initial surge in 2020. This prospective international observation study (The COVIP study) recruited patients aged 70 years or older (ClinicalTrials.gov ID: NCT04321265) admitted to an intensive care unit (ICU) with COVID-19 disease from March 2020 to February 2021. In addition to serial lactate values (arterial blood gas analysis), we recorded several parameters, including SOFA score, ICU procedures, limitation of care, ICU- and 3-month mortality. A lactate concentration ≥ 2.0 mmol/L on the day of ICU admission (baseline) was defined as abnormal. The primary outcome was ICU-mortality. The secondary outcomes 30-day and 3-month mortality. In total, data from 2860 patients were analyzed. In most patients (68%), serum lactate was lower than 2 mmol/L. Elevated baseline serum lactate was associated with significantly higher ICU- and 3-month mortality (53% vs. 43%, and 71% vs. 57%, respectively, p < 0.001). In the multivariable analysis, the maximum lactate concentration on day 1 was independently associated with ICU mortality (aOR 1.06 95% CI 1.02-1.11; p = 0.007), 30-day mortality (aOR 1.07 95% CI 1.02-1.13; p = 0.005) and 3-month mortality (aOR 1.15 95% CI 1.08-1.24; p < 0.001) after adjustment for age, gender, SOFA score, and frailty. In 826 patients with baseline lactate ≥ 2 mmol/L sufficient data to calculate the difference between maximal levels on days 1 and 2 (∆ serum lactate) were available. A decreasing lactate concentration over time was inversely associated with ICU mortality after multivariate adjustment for SOFA score, age, Clinical Frailty Scale, and gender (aOR 0.60 95% CI 0.42-0.85; p = 0.004). In critically ill old intensive care patients suffering from COVID-19, lactate and its kinetics are valuable tools for outcome prediction. Trial registration number : NCT04321265. The online version contains supplementary material available at 10.1186/s13613-021-00911-8.